Showing 6191-6200 of 9536 results for "".
- Study: Gut Permeability Biomarker Linked with AD Symptom Reliefhttps://practicaldermatology.com/news/study-gut-permeability-biomarker-linked-with-ad-symptom-relief/2485110/New research suggests serum D-lactate levels may predict clinical response to washed microbiota transplantation (WMT), showing the role of intestinal barrier dysfunction in atopic dermatitis (AD). Researchers for the prospective
- Acne Incidence Higher with Higher-Dose LNG-IUS, Meta-Analysis Findshttps://practicaldermatology.com/news/acne-incidence-higher-with-higher-dose-lng-ius-meta-analysis-finds/2485045/A new systematic review and meta-analysis shows the incidence of acne among users of the levonorgestrel-releasing intrauterine system (LNG-IUS), identifying both dosage and age as influential factors. The review included nine ra
- Contact Dermatitis, Unlabeled Ingredients Among Concerns in Self-Tannershttps://practicaldermatology.com/news/contact-dermatitis-unlabeled-ingredients-among-concerns-in-self-tanners/2485034/A recent review in the Journal of Drugs in Dermatology raised some concerns regarding ingredient safety and adverse reactions. Researchers on the study analyzed the top 50 best-selling sunless tanning products on Amazon
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- Systematic Review Shows BTX Effective for Ischemic Digital Complicationshttps://practicaldermatology.com/news/systematic-review-btx-effective-for-ischemic-digital-complications/2484841/Botulinum toxin (BTX) injections may offer a promising rescue therapy for patients with refractory digital ischemia, ulcers, or gangrene associated with systemic sclerosis and other vasculopathies, according to findings from a systematic review in
- Study: Tirzepatide Shows Early Efficacy in Hidradenitis Suppurativahttps://practicaldermatology.com/news/study-tirzepatide-shows-early-efficacy-in-hidradenitis-suppurativa/2484716/New research shows dual GLP-1/GIP inhibitor tirzepatide, a dual GLP-1/GIP receptor agonist currently approved for type 2 diabetes and obesity, may offer a novel therapeutic option for patients with moderate-to-severe hidradenitis suppurativa (HS), according to a sm
- New UK Data Raises Concerns on Fusidic Acid Resistance in Pediatric Patientshttps://practicaldermatology.com/news/regional-uk-data-raises-alarm-on-fusidic-acid-resistance-in-pediatric-patients/2484590/A recent UK study showed a shift in antimicrobial resistance patterns in Staphylococcus aureus (S. aureus) isolates associated with atopic dermatitis (AD), which the authors said raised concerns about the use of topical fusidic acid.
- AI Model Accurately Scores Psoriasis Severity from Clinical Imageshttps://practicaldermatology.com/news/ai-model-accurately-scores-psoriasis-severity-from-clinical-images/2484588/A new study demonstrates the potential of artificial intelligence (AI) to improve the consistency and objectivity of psoriasis severity assessments based on 2D clinical images. Researchers for the study used the YOLOv8 deep lear
- Study: Itch and Rash Severity Linked to Biologic Use in Eczemahttps://practicaldermatology.com/news/itch-and-rash-severity-linked-to-biologic-use-in-eczema-paper/2484499/Data from a recent pre-proof in the Journal of the American Academy of Dermatology highlights that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic de